REFERENCES
1. Liu J, Barrett JS, Leonardi ET, et al. Natural History and Real-World
Data in Rare Diseases: Applications, Limitations, and Future
Perspectives. J Clin Pharmacol . 2022;62 Suppl 2:S38-S55.
doi:10.1002/jcph.2134
2. Hiramatsu K, Barrett A, Miyata Y, PhRMA Japan Medical Affairs
Committee Working Group 1. Current Status, Challenges, and Future
Perspectives of Real-World Data and Real-World Evidence in Japan.Drugs Real World Outcomes . 2021;8(4):459-480.
doi:10.1007/s40801-021-00266-3
3. Pharmaceuticals and Medical Devices Agency. Accessed June 25, 2023.
https://www.pmda.go.jp/
4. Tsuchiya M, Obara T, Miyazaki M, Noda A, Takamura C, Mano N. The
quality assessment of the Japanese Adverse Drug Event Report database
using vigiGrade. Int J Clin Pharm . 2020;42(2):728-736.
doi:10.1007/s11096-020-00969-7
5. Suga Y, Uchida M, Suzuki S, et al. Current Status of Adverse Events
Related with Opioid Analgesics in Japan: Assessment Based on Japanese
Adverse Drug Event Report Database. Biol Pharm Bull .
2019;42(5):801-806. doi:10.1248/bpb.b18-00997
6. Wilson AM, Thabane L, Holbrook A. Application of data mining
techniques in pharmacovigilance. Br J Clin Pharmacol .
2004;57(2):127-134. doi:10.1046/j.1365-2125.2003.01968.x
7. Lau EMT, Giannoulatou E, Celermajer DS, Humbert M. Epidemiology and
treatment of pulmonary arterial hypertension. Nat Rev Cardiol .
2017;14(10):603-614. doi:10.1038/nrcardio.2017.84
8. Zhang ZQ, Zhu SK, Wang M, et al. New progress in diagnosis and
treatment of pulmonary arterial hypertension. J Cardiothorac
Surg . 2022;17(1):216. doi:10.1186/s13019-022-01947-y
9. Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity
and mortality in pulmonary arterial hypertension. N Engl J Med .
2013;369(9):809-818. doi:10.1056/NEJMoa1213917
10. Sitbon O, Channick R, Chin KM, et al. Selexipag for the Treatment of
Pulmonary Arterial Hypertension. N Engl J Med .
2015;373(26):2522-2533. doi:10.1056/NEJMoa1503184
11. Galiè N, Barberà JA, Frost AE, et al. Initial Use of Ambrisentan
plus Tadalafil in Pulmonary Arterial Hypertension. N Engl J Med .
2015;373(9):834-844. doi:10.1056/NEJMoa1413687
12. Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for
the diagnosis and treatment of pulmonary hypertension. Eur Respir
J . 2023;61(1):2200879. doi:10.1183/13993003.00879-2022
13. Pitre T, Su J, Cui S, et al. Medications for the treatment of
pulmonary arterial hypertension: a systematic review and network
meta-analysis. Eur Respir Rev . 2022;31(165):220036.
doi:10.1183/16000617.0036-2022
14. Leber L, Beaudet A, Muller A. Epidemiology of pulmonary arterial
hypertension and chronic thromboembolic pulmonary hypertension:
identification of the most accurate estimates from a systematic
literature review. Pulm Circ . 2021;11(1):2045894020977300.
doi:10.1177/2045894020977300
15. Preston IR, Roberts KE, Miller DP, et al. Effect of Warfarin
Treatment on Survival of Patients With Pulmonary Arterial Hypertension
(PAH) in the Registry to Evaluate Early and Long-Term PAH Disease
Management (REVEAL). Circulation . 2015;132(25):2403-2411.
doi:10.1161/CIRCULATIONAHA.115.018435
16. Ogawa A, Satoh T, Tamura Y, Fukuda K, Matsubara H. Survival of
Japanese Patients With Idiopathic/Heritable Pulmonary Arterial
Hypertension. Am J Cardiol . 2017;119(9):1479-1484.
doi:10.1016/j.amjcard.2017.01.015
17. Tamura Y, Kumamaru H, Satoh T, et al. Effectiveness and Outcome of
Pulmonary Arterial Hypertension-Specific Therapy in Japanese Patients
With Pulmonary Arterial Hypertension. Circ J . 2017;82(1):275-282.
doi:10.1253/circj.CJ-17-0139
18. Hoeper MM, Pausch C, Grünig E, et al. Temporal trends in pulmonary
arterial hypertension: results from the COMPERA registry. Eur
Respir J . 2022;59(6):2102024. doi:10.1183/13993003.02024-2021
19. Ogawa A, Ejiri K, Matsubara H. Long-term patient survival with
idiopathic/heritable pulmonary arterial hypertension treated at a single
center in Japan. Life Sci . 2014;118(2):414-419.
doi:10.1016/j.lfs.2014.01.077
20. Tamura Y, Tamura Y, Taniguchi Y, et al. Clinical Management and
Outcomes of Patients With Portopulmonary Hypertension Enrolled in the
Japanese Multicenter Registry. Circ Rep . 2022;4(11):542-549.
doi:10.1253/circrep.CR-22-0098
21. Tamura Y, Kumamaru H, Inami T, et al. Changes in the Characteristics
and Initial Treatments of Pulmonary Hypertension Between 2008 and 2020
in Japan. JACC Asia . 2022;2(3):273-284.
doi:10.1016/j.jacasi.2022.02.011
22. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous
intravenous epoprostenol (prostacyclin) with conventional therapy for
primary pulmonary hypertension. N Engl J Med .
1996;334(5):296-301. doi:10.1056/NEJM199602013340504
23. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous
epoprostenol infusion in primary pulmonary hypertension: prognostic
factors and survival. J Am Coll Cardiol . 2002;40(4):780-788.
doi:10.1016/s0735-1097(02)02012-0
24. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary
hypertension: the impact of epoprostenol therapy. Circulation .
2002;106(12):1477-1482. doi:10.1161/01.cir.0000029100.82385.58
25. Chaumais MC, Jobard M, Huertas A, et al. Pharmacokinetic evaluation
of continuous intravenous epoprostenol. Expert Opin Drug Metab
Toxicol . 2010;6(12):1587-1598. doi:10.1517/17425255.2010.534458
26. Bourge RC, Waxman AB, Gomberg-Maitland M, et al. Treprostinil
Administered to Treat Pulmonary Arterial Hypertension Using a Fully
Implantable Programmable Intravascular Delivery System: Results of the
DelIVery for PAH Trial. Chest . 2016;150(1):27-34.
doi:10.1016/j.chest.2015.11.005
27. Richter MJ, Harutyunova S, Bollmann T, et al. Long-term safety and
outcome of intravenous treprostinil via an implanted pump in pulmonary
hypertension. J Heart Lung Transplant . 2018;37(10):1235-1244.
doi:10.1016/j.healun.2018.06.006
28. Olschewski H, Simonneau G, Galiè N, et al. Inhaled iloprost for
severe pulmonary hypertension. N Engl J Med . 2002;347(5):322-329.
doi:10.1056/NEJMoa020204
29. Barst RJ, McGoon M, McLaughlin V, et al. Beraprost therapy for
pulmonary arterial hypertension. J Am Coll Cardiol .
2003;41(12):2119-2125. doi:10.1016/s0735-1097(03)00463-7
30. Kloner RA, Hutter AM, Emmick JT, Mitchell MI, Denne J, Jackson G.
Time course of the interaction between tadalafil and nitrates. J
Am Coll Cardiol . 2003;42(10):1855-1860. doi:10.1016/j.jacc.2003.09.023
31. Hoeper MM, Al-Hiti H, Benza RL, et al. Switching to riociguat versus
maintenance therapy with phosphodiesterase-5 inhibitors in patients with
pulmonary arterial hypertension (REPLACE): a multicentre, open-label,
randomised controlled trial. Lancet Respir Med .
2021;9(6):573-584. doi:10.1016/S2213-2600(20)30532-4
32. Galiè N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the
treatment of pulmonary arterial hypertension: results of the ambrisentan
in pulmonary arterial hypertension, randomized, double-blind,
placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2.Circulation . 2008;117(23):3010-3019.
doi:10.1161/CIRCULATIONAHA.107.742510
33. Humbert M, Segal ES, Kiely DG, Carlsen J, Schwierin B, Hoeper MM.
Results of European post-marketing surveillance of bosentan in pulmonary
hypertension. Eur Respir J . 2007;30(2):338-344.
doi:10.1183/09031936.00138706
34. Ulrich S, Saxer S, Hasler ED, et al. Effect of domiciliary oxygen
therapy on exercise capacity and quality of life in patients with
pulmonary arterial or chronic thromboembolic pulmonary hypertension: a
randomised, placebo-controlled trial. Eur Respir J .
2019;54(2):1900276. doi:10.1183/13993003.002762019
35. Tamura Y, Kimura M, Takei M, et al. Oral vasopressin receptor
antagonist tolvaptan in right heart failure due to pulmonary
hypertension. Eur Respir J . 2015;46(1):283-286.
doi:10.1183/09031936.00044915
Table 1 Demographics and clinical outcomes of the patients with
pulmonary arterial hypertension reported in the Japanese Adverse Drug
Event Report database